ITGAX and neoplasm: CD11b+Ly6C+CD11c+MHCII+ moDCs comprise the majority of tumor-resident APCs in both B16 and MC38 tumors, and they are correlated in abundancy with effector TILs only in successfully αPD1-treated conditions only in MC38.